DANBURY, Conn. and WESTLAKE VILLAGE, Calif. — MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases, announced today that it has fully enrolled 305 patients living with type 1 or type 2 diabetes in its...
Latest News
MANTECA — Manteca twins were born with a rare disease that affects just more than 1,200 globally. It’s left them stunted emotionally and physically. Augustin Polanco preps his twin 19-year-old daughters for school. Esperanza and Libertad, or Espy and Libby for short, suffer from a rare disease called syngap1. It’s...
SAN DIEGO, CA ― The targeted therapy combination of ibrutinib and venetoclax significantly improved progression-free survival (PFS) and achieved an overall remission rate in 82% of patients with relapsed/refractory mantle cell lymphoma (MCL), according to researchers at The University of Texas MD Anderson Cancer Center. Results from the Phase III...
PHOENIX, Arizona — High-grade gliomas are cancerous tumors that spread quickly in the brain or spinal cord. In a new study led by Mayo Clinic, researchers found invasive brain tumor margins of high-grade glioma (HGG) contain biologically distinct genetic and molecular alterations that point to aggressive behavior and disease recurrence. The findings...
For decades they have been looking for the few and the proud. In Chris Kaag, the Marines found such a man. A Marine is a Marine. There is no such thing as a former Marine, according to the 35th Commandant of the Marine Corps, Gen. James F. Amos. When your...
RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that due to the impact of the COVID-19 Omicron variant on hospital resources and an unexpected interruption of clinical supply material associated with IV ganaxolone, the...
RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the appointment of Saraswathy (“Sara”) Nochur, Ph.D., to its Board of Directors. “Sara brings tremendous experience and success in managing global regulatory and drug development and...
RADNOR, Pa.- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced the hiring of Steven E. Pfanstiel as Chief Financial Officer and Lisa Lejuwaan to the newly created position of Vice President of Sales. The appointments reflect...
RADNOR, Pa. – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Santiago Arroyo, M.D., Ph.D., to its Board of Directors. Dr. Arroyo brings more than 30 years of experience in academic neurology and pharmaceutical...
Cells that form cutaneous squamous cell carcinoma tumours prepare themselves to migrate to the lymph nodes to metastasise other organs, and they make changes so that they can survive this process. According to a study led by researchers from the Inflammatory and Neoplastic Dermatological Diseases Research Group at the Hospital del Mar Medical Research Institute, published in the journal Life Science Alliance, these cells stop consuming glucose so that they can survive by using LDL cholesterol molecules, the so-called bad cholesterol. This new marker may be a promising candidate for treatments involving lipid metabolism inhibitors targeting these cells to prevent metastasis.